Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Receivables (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Receivables for 16 consecutive years, with $355789.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables fell 97.51% year-over-year to $355789.0, compared with a TTM value of $355789.0 through Sep 2025, down 97.51%, and an annual FY2024 reading of $13.8 million, up 1990.85% over the prior year.
  • Receivables was $355789.0 for Q3 2025 at China Pharma Holdings, down from $14.0 million in the prior quarter.
  • Across five years, Receivables topped out at $14.4 million in Q4 2023 and bottomed at $275244.0 in Q2 2023.
  • Average Receivables over 5 years is $5.2 million, with a median of $1.5 million recorded in 2021.
  • The sharpest move saw Receivables surged 4982.61% in 2024, then plummeted 97.51% in 2025.
  • Year by year, Receivables stood at $1.5 million in 2021, then tumbled by 69.02% to $450670.0 in 2022, then soared by 3106.0% to $14.4 million in 2023, then dropped by 4.14% to $13.8 million in 2024, then plummeted by 97.43% to $355789.0 in 2025.
  • Business Quant data shows Receivables for CPHI at $355789.0 in Q3 2025, $14.0 million in Q2 2025, and $367947.0 in Q1 2025.